Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 59, Issue 1, Pages 38-42Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2006.10.007
Keywords
toxicology; pharmaceutical impurities; European medicines agency (EMEA); genotoxic impurities
Categories
Ask authors/readers for more resources
While the use of pharmaceuticals is always a balance of risks and benefits, the same is not true for impurities in pharmaceuticals; impurities convey only risk. A number of international guidelines and regional guidances instruct drug developers and regulatory agencies on how to evaluate and control impurities in drug substances and drug products. While impurities should always be reduced to the lowest levels that are reasonably practical, it is acknowledged that impurities cannot be reduced to zero and specifications for impurities need to be established. This chapter discusses practical and theoretical methods for qualification of different classes of impurities. (c) 2006 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available